HRT

HRT, what you need to know in 2026

If your doctor told you HRT is dangerous, she may have learned that in 2002. The science has moved on. Here's where we actually are now, what the evidence says, who is and isn't a candidate, the difference between transdermal and oral, and the script for the appointment that gets you somewhere.

What HRT is (and isn't)

HRT, Hormone Replacement Therapy, sometimes called MHT (Menopausal Hormone Therapy), is the practice of supplementing the hormones your ovaries have stopped producing in sufficient amounts. In modern prescribing, that almost always means two things:

• · Estradiol, bio-identical 17β-estradiol. Delivered through a skin patch, a metered gel, a daily spray or, less commonly, a tablet.
• · A progestogen, to protect the lining of the uterus from unopposed estrogen. Only needed if you still have a uterus. Micronized progesterone (Prometrium) is the preferred option; the Mirena IUD is an alternative.

HRT is not compulsory. Plenty of women never need it, never want it, or get through the transition with foundational changes alone. It is also not a beauty treatment, not a weight-loss drug, and not a confirmed prevention strategy for dementia (the evidence is promising but not yet conclusive).

The WHI study and what got misread

On 9 July 2002, the Women's Health Initiative announced the early termination of one arm of its HRT trial. The headline that swept the world: HRT increases breast cancer by 26%. Within 12 months, half of the six million American women on HRT had stopped. Prescribing collapsed worldwide. A generation of doctors trained after 2002 learned, in effect, that HRT was dangerous.

The reality of the trial, read carefully:

• · “26% increase” was the relative risk. In absolute terms, it amounted to roughly 6 extra breast cancer cases per 10,000 women per year, a similar order of magnitude to drinking one glass of wine a day.
• · The drug tested was conjugated equine estrogen plus medroxyprogesterone acetate (Prempro). That is not the modern HRT prescribed today.
• · Average age at enrolment was 63. Only 10% of participants were 50–54, the age at which women actually start HRT. Most were 10–20 years past their final period.
• · 70% of participants were overweight or obese, half had been smokers, a third were on antihypertensives. Not a representative population.
• · The other arm of WHI, estrogen alone, in women who had had hysterectomies, showed a reduction in breast cancer of about 23%, sustained on 13-year follow-up.

A 2017 follow-up of the original WHI cohort in JAMA found no excess mortality from breast cancer, cardiovascular disease or any cause after 18 years of follow-up. The Menopause Society's 2022 position statement, endorsed by more than 30 international bodies including the Endocrine Society, walked the consensus all the way back. Current menopause guidelines are now aligned with that consensus.

The timing hypothesis, what window matters

The biggest single insight to come out of the post-WHI reanalysis is the timing hypothesis: estrogen protects healthy blood vessels but may aggravate already-diseased ones. So the cardiovascular benefit of HRT depends on when you start.

• · Starting HRT within 10 years of your final period (or before age 60) is associated, in pooled analyses of 23 randomised trials, with a 30% lower risk of heart attack and cardiac death.
• · Starting HRT more than 10 years after menopause shows no clear cardiovascular benefit.
• · Starting HRT more than 20 years after menopause is associated with a small but real cardiovascular risk increase.

Two RCTs largely confirmed the window: KEEPS (Kronos Early Estrogen Prevention Study, 2014) and ELITE (Early versus Late Intervention Trial with Estradiol, 2016). Together they showed that women started on transdermal or oral estradiol within six years of menopause had better arterial measures than those who started ten or more years later. The window matters.

Types of HRT

Estradiol, the preferred estrogen

17β-estradiol is the bio-identical estrogen, structurally identical to what your ovaries used to make. It is dispensed as patches (Vivelle-Dot, Climara, Minivelle), a metered gel (Divigel, EstroGel, Elestrin) and a daily spray (Evamist). Conjugated equine estrogen (Premarin) is rarely prescribed in 2026 outside very specific cases.

Progestogens, micronized > synthetic

If you still have a uterus, you need a progestogen alongside estradiol to prevent endometrial hyperplasia. Three main options in practice:

• · Micronized progesterone (Prometrium), bio-identical, taken orally (usually 100 mg nightly continuous, or 200 mg for 12 days a month cyclically). Mildly sedating, which is useful at bedtime. Lowest breast cancer signal of the options. First-line in most contemporary guidance.
• · Mirena IUD, a levonorgestrel-releasing device. Provides endometrial protection for five years, also contraception, and reduces menstrual bleeding. Useful if you struggle to remember a daily tablet.
• · Synthetic progestins (norethindrone, MPA, dydrogesterone), historically common; still used in combined preparations. Slightly higher breast cancer signal than micronized progesterone in observational data.

Testosterone, the under-prescribed option

For women with persistent low libido (HSDD) despite adequate estradiol, testosterone is the evidence-based add-on. It is prescribed off-label (for example as AndroGel or Testim) in a small daily quantity (roughly one-tenth of a male dose, applied to the outer thigh). The 2019 global consensus statement on testosterone in women supports its use for HSDD; current menopause guidelines endorse it as an option after estrogen has been optimized. It is not approved for cognitive symptoms or fatigue, and the evidence for those uses is weak.

Transdermal vs oral, why route matters

One of the cleanest pieces of evidence in modern menopause medicine: transdermal estradiol does not raise the risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism) above the baseline of an age-matched woman not on HRT. Oral estradiol does, modestly, but measurably.

The mechanism is the first-pass effect. Oral estradiol is absorbed from the gut and processed by the liver before it reaches the bloodstream. The liver responds by producing more clotting factors, more SHBG (which lowers free testosterone, often flattening libido), and more triglycerides. A transdermal patch, gel or spray bypasses this circuit entirely.

For most women starting HRT in 2026, transdermal is now the default route. Oral estradiol is reserved for women who simply prefer a tablet, who can't tolerate patches, or who have specific reasons to use it.

Real risks vs perceived risks

The honest absolute numbers, drawn from current Menopause Society summaries and leading clinical guidelines, for a typical woman aged 50–59 on combined HRT for five years:

• · Breast cancer, roughly 4 extra cases per 1,000 women over five years with combined estrogen-progestogen HRT. Estrogen alone shows no increase (and the WHI data shows a reduction). For comparison: drinking two alcoholic drinks a day produces a similar increase; being overweight produces a much larger one.
• · Stroke, small increase with oral estrogen, no increase with transdermal.
• · VTE (clot), small increase with oral, no increase with transdermal.
• · Endometrial cancer, increased with unopposed estrogen in women who still have a uterus. Properly combined HRT eliminates this risk.

On the benefit side: a roughly 30% reduction in cardiovascular events when started within the window, a 20–40% reduction in type 2 diabetes incidence, a reduction in osteoporotic fracture, near-elimination of vasomotor symptoms in around 95% of users, and improvement in mood, sleep and joint pain for the majority.

Who is and isn't a candidate

The shortlist of absolute contraindications for systemic HRT is smaller than most people think: active estrogen-receptor-positive breast cancer, active endometrial cancer (until treated), undiagnosed vaginal bleeding, active venous thromboembolism, severe active liver disease.

History of breast cancer is a relative contraindication and a conversation to have with your oncologist; for many survivors, vaginal estrogen for genitourinary symptoms is still safe (this has been the position of major bodies since 2018). A family history of breast cancer, in itself, is not a contraindication.

Women with primary ovarian insufficiency (menopause before 40) should be on HRT until at least the average age of natural menopause, this is preventive, not optional. Current menopause guidelines are explicit on this point.

How to discuss HRT with your doctor, the script

Eight-minute appointment, three sentences. Try this:

• · “I've tracked my cycles and symptoms for the past [X] months. I think I'm in perimenopause. The pattern is [your top 3 symptoms].”
• · “Based on current menopause guidelines and the Menopause Society 2022 statement, I'd like to discuss transdermal estradiol plus micronized progesterone.”
• · “Can we talk about a starting dose and how we'll review it at three months?”

If your doctor declines or pushes back without a clear medical reason, you can ask for a referral to a menopause specialist or a dedicated menopause clinic. Citing the guidelines by name, such as current menopause guidelines or the Menopause Society statement, tends to be effective.

Private menopause specialists, if your doctor is blocked

The Menopause Society maintains a directory of certified practitioners. Typical telehealth menopause consultations run $200–$400 for a first appointment, $100–$200 for follow-ups. Many specialists do video consultations, which makes geography less of a constraint. Prescriptions issued privately can often be transferred to your primary care doctor for ongoing refills, ask in advance.

A note on services that promise “personalized bio-identical compounded HRT” outside the regulated market: the Menopause Society and the FDA both advise against. These products are not pharmaceutically quality-controlled. Body-identical estradiol and micronized progesterone, on a standard FDA-approved prescription, are already bio-identical.

Related reading

If you're not sure which phase you're in, the 6 phases of menopause explained walks through STRAW+10 in plain English. If you're trying to work out which of your symptoms are hormonal, all 47 menopause symptoms is the most-cited summary on this site. And if you're newly arrived here, start with what is perimenopause.